NCT00625274

A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This study looks at controlling intragastric pH following administration of esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg taken orally, once daily in patients taking either non-selective or cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs).

Conditions

• Heartburn
• Upper Abdominal Pain
• Nausea
• Acid Regurgitation

Interventions

Type	Name	Description
DRUG	Esomeprazole	40mg Oral
DRUG	Lansoprazole	30mg Oral
DRUG	Pantoprazole	40mg Oral

Timeline

• Start date: 2004-06-01
• Primary completion: 2004-11-01
• Completion: 2004-11-01
• First posted: 2008-02-28
• Last updated: 2008-02-28